New Drug Approved for Pancreatic Cancer Treatment
The US Food and Drug Administration has approved the drug daraxonrasib, which increases average survival time in advanced-stage patients.
The US Food and Drug Administration (FDA) has announced that it has given official approval for the use of the drug called daraxonrasib in pancreatic cancer treatment.
Efficacy Duration of the Drug
In advanced-stage clinical trials, the average survival time of patients using the new drug was recorded as 13.2 months. In the control group receiving standard chemotherapy, this period remained at the level of 6.6 months.
Clinical Trial Details
A total of 500 patients participated in the research process. It was determined that the survival time of patients who took this pill-form drug regularly every day increased significantly.
Mechanism of Action and Objective
Daraxonrasib targets the mutated KRAS gene, which is found in more than 90 percent of pancreatic tumors and triggers cancer development. By deactivating the gene, it helps prevent the spread of cancer.
Disease Statistics
According to data from the American Cancer Society, approximately 67,000 people are diagnosed with pancreatic cancer each year in the US. This type of cancer has the highest mortality rate among all major cancers.
FDA Approval Process
The FDA had granted the drug 'Breakthrough Therapy' status, which requires expedited review, in 2025. Angelo de Claro, director of the Oncology Center of Excellence, stated that the drug addresses an unmet medical need.
Observed Side Effects
Among the most common side effects of the treatment identified during clinical trials is skin rash. Additionally, diarrhea, nausea, fatigue, and vomiting were other effects reported by patients.